Orlistat PD Endpoint BE study [Regulatives / Guidelines]

posted by NK – India, 2024-04-30 06:33 (371 d 08:40 ago) – Posting: # 23966
Views: 1,732

Dear All,

As per the USFDA recommendation, if we conduct the Orlistat PD Endpoint BE study, we may have data (fecal fat) for Baseline, Test, Ref1 and Ref2

Can anyone explain how to analyze the pharmacodynamic study data step by step? how to establish dose response relationship?. Any example dataset are available?

Kindly suggest, which software (WinNonlin/SAS/etc…) is required to analyze these data.

Regards
NK

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
82 visitors (0 registered, 82 guests [including 9 identified bots]).
Forum time: 15:14 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5